Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease

  • Felice Gragnano
  • Fabio Fimiani
  • Marco Di Maio
  • Arturo Cesaro
  • Giuseppe Limongelli
  • Davide Cattano
  • Paolo CalabròEmail author
CE - Research Letter to the Editor


Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, acting by either accelerating atherosclerosis progression or inducing a prothrombotic/antifibrinolytic systemic milieu [1, 2, 3]. Several studies support the relevant role of Lp(a) in the occurrence of coronary events, especially in patients with premature coronary artery disease (CAD) [4, 5, 6]. However, the association of elevated Lp(a) levels with the risk of recurrent cardiovascular events in patients with a prior coronary event optimally treated with statins remains controversial [7]. We sought to assess the impact of Lp(a) levels on the recurrence of cardiovascular events in patients with premature CAD treated with percutaneous coronary intervention (PCI).


This prospective single-center study enrolled consecutive young patients (aged less than 50 years) undergoing first-ever PCI for stable CAD (SCAD) or acute coronary syndrome (ACS) (both ST-segment elevation...


Lipoprotein(a) Dyslipidemia Acute coronary syndrome Coronary artery disease Percutaneous coronary intervention 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

The study was carried out according to Declaration of Helsinki.

Informed consent

Patients gave their informed consent to participate to the study.


  1. 1.
    Ferretti G, Bacchetti T, Johnston TP et al (2018) Lipoprotein(a): a missing culprit in the management of athero-thrombosis? J Cell Physiol 233:2966–2981. CrossRefGoogle Scholar
  2. 2.
    Gragnano F, Calabrò P (2018) Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis 269:219–228. CrossRefGoogle Scholar
  3. 3.
    Fogacci F, Cicero AF, D’Addato S, D’Agostini L, Rosticci M, Giovannini M, Bertagnin E, Borghi C, Brisighella Heart Study Group (2017) Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. Eur J Intern Med 37:49–55. CrossRefGoogle Scholar
  4. 4.
    Scanu AM (1992) Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA, J Am Med Assoc 267:3326–3329. CrossRefGoogle Scholar
  5. 5.
    Rallidis LS, Pavlakis G, Foscolou A et al (2018) High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis 269:29–34. CrossRefGoogle Scholar
  6. 6.
    Marcucci R, Brunelli T, Fedi S et al (2005) Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. Eur J Clin Invest 35:1–7. CrossRefGoogle Scholar
  7. 7.
    Schwartz GG, Ballantyne CM, Barter PJ et al (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol 3:164–168. CrossRefGoogle Scholar
  8. 8.
    Milionis HJ, Filippatos TD, Loukas T et al (2006) Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 187:170–176. CrossRefGoogle Scholar
  9. 9.
    Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692–711. CrossRefGoogle Scholar
  10. 10.
    Chiarugi L, Prisco D, Antonucci E et al (2001) Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 154:129–135CrossRefGoogle Scholar
  11. 11.
    Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058l. CrossRefGoogle Scholar
  12. 12.
    Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S (2019) Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc 8:e010932. CrossRefGoogle Scholar
  13. 13.
    Gragnano F, Natale F, Concilio C et al (2018) Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. J Cardiovasc Med 19:75–77. Google Scholar
  14. 14.
    Schettler VJJ, Neumann CL, Peter C et al (2017) Current insights into the German lipoprotein apheresis registry (GLAR)—almost 5 years on. Atheroscler Suppl 30:50–55. CrossRefGoogle Scholar
  15. 15.
    Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253. CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Division of CardiologyA.O.R.N. Sant’Anna e San Sebastiano, F. PalascianoCasertaItaly
  2. 2.Division of Cardiology, Department of Translational Medical SciencesUniversity of Campania “Luigi Vanvitelli”NaplesItaly
  3. 3.McGovern Medical SchoolUTHealth at HoustonHoustonUSA

Personalised recommendations